NEW YORK (GenomeWeb News) - Tethys Bioscience has named former Chief Business Officer Michael Richey to be president, and it has added several members to its management team.
The company said that Mohan Iyer will take over Richey's role as CBO. Richey formerly was managing director of healthcare investment banking at Burrill & Company's Merchant Bank. Eric Book has taken on the role of chief medical officer, Brian Best is serving as VP of commercial operations, and Ted Tarasow has been named VP of product development and laboratory operations
Agilent Technologies has promoted Marie Oh Huber to be senior VP, general counsel, and secretary. Huber already served as VP, deputy general counsel, and assistant secretary, and she has managed the team that advises the board of directors and the management team on mergers and acquisitions, corporate governance, securities, and other issues. She previously worked for a decade at Hewlett-Packard as an M&A and securities attorney.
The firm also announced that Mike McMullen was promoted to senior vice president of Agilent and president of the Chemical Analysis Group, while Nick Roelofs was promoted to Agilent SVP and president of the Life Sciences Group. Each had previously been vice president and general manager of his respective unit within the Life Science and Chemical Analysis Group, which was split in two this week.
Pacific Biometrics has appointed Mario Ehlers to serve on the company's board of directors, taking a seat vacated by Terry Giles, who has resigned after reaching a deal to provide the firm with $4 million loan. Ehlers currently is deputy director of the Clinical Trials Group at the Immune Tolerance Network.
Osmetech has named Jon Faiz Kayyem to be CEO while the company searches for a new CEO. Kayyem was founder of the company's core molecular diagnostics business and is a member of the board. Kayyem had formerly served as a joint interim CEO with Chris Gleeson, who also is board chairman, and now he will take over the position full-time.
In addition, Osmetech board member Mark Lappe has resigned from his position to focus on his management consulting business.
Will Dracup, who is CEO of Biosignatures, will step down from his other position as a non-executive director on the board at Immunodiagnostic Systems. Dracup made the decision after the two companies signed a commercial collaboration agreement.
Orchid Cellmark's George Poste will not stand for re-election for his position as chairman of the company's board of directors, and the company has named James Beery to replace him. Poste has been a member of the company's board since 2000.
Stephen Minger has joined GE Healthcare's Life Science business as head of the R&D for Cell Technologies. He joins the firm from King's College London, where he served as director of the Stem cell Biology Laboratory.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People in the News, a weekly roundup of industry comings and goings.